Results 51 to 60 of about 461,541 (350)

Rapid hematologic responses improve outcomes in patients with very advanced (stage IIIb) cardiac immunoglobulin light chain amyloidosis

Haematologica, 2018
Systemic AL amyloidosis (AL) is caused by deposition of misfolded immunoglobulin light chains, leading to potentially catastrophic visceral dysfunction.[1][1] Outcomes are heterogeneous, but cardiac involvement is a key survival predictor.
R. Manwani, Darren Foard, S. Mahmood, S. Sachchithanantham, T. Lane, C. Quarta, T. Youngstein, T. Rezk, H. Lachmann, J. Gillmore, M. Fontana, C. Whelan, P. Hawkins, A. Wechalekar   +13 more
semanticscholar   +1 more source

Immunoglobulin light chains in medaka (Oryzias latipes) [PDF]

Immunogenetics, 2013
The gene segments encoding antibodies have been studied in many capacities and represent some of the best-characterized gene families in traditional animal disease models (mice and humans). To date, multiple immunoglobulin light chain (IgL) isotypes have been found in vertebrates and it is unclear as to which isotypes might be more primordial in nature.
Magadan-Mompo, Susana, Zimmerman, Anastasia M., Sanchez-Espinel, Christian, Gambon-Deza, Francisco   +3 more
openaire   +5 more sources

Treatment of IgM-associated immunoglobulin light-chain amyloidosis with rituximab-bendamustine.

Blood, 2018
TO THE EDITOR: Systemic amyloid light-chain amyloidosis (AL) is characterized by deposition of misfolded immunoglobulin light chains within organs. AL with an immunoglobulin M (IgM) monoclonal protein (IgM-AL) accounts for 5% to 7% of AL and exhibits ...
R. Manwani, S. Sachchithanantham, S. Mahmood, Darren Foard, F. Sharpley, T. Rezk, T. Lane, C. Quarta, M. Fontana, H. Lachmann, J. Gillmore, C. Whelan, P. Hawkins, A. Wechalekar   +13 more
semanticscholar   +1 more source

First report of safety and efficacy of daratumumab in 2 cases of advanced immunoglobulin light chain amyloidosis.

Blood, 2016
To the editor: Immunoglobulin light chain amyloidosis (AL) with advanced cardiac involvement is characterized by short survival. Outcomes are especially poor for patients who have multiorgan involvement and coexisting multiple myeloma and do not achieve
T. Sher, B. Fenton, A. Akhtar, M. Gertz
semanticscholar   +1 more source

FoxO1 signaling in B cell malignancies and its therapeutic targeting

FEBS Letters, EarlyView.
FoxO1 has context‐specific tumor suppressor or oncogenic character in myeloid and B cell malignancies. This includes tumor‐promoting properties such as stemness maintenance and DNA damage tolerance in acute leukemias, or regulation of cell proliferation and survival, or migration in mature B cell malignancies.
Krystof Hlavac, Petra Pavelkova, Laura Ondrisova, Marek Mraz   +3 more
wiley   +1 more source

Per-sample immunoglobulin germline inference from B cell receptor deep sequencing data [PDF]

PLoS Comput Biol 15(7): e1007133 (2019), 2017
The collection of immunoglobulin genes in an individual's germline, which gives rise to B cell receptors via recombination, is known to vary significantly across individuals. In humans, for example, each individual has only a fraction of the several hundred known V alleles.
arxiv   +1 more source

Light-chain amyloidosis with dysphagia as the main symptom: a case report

Journal of Medical Case Reports
Background Immunoglobulin light-chain amyloidosis is a relatively rare condition with a worldwide incidence of 5.1–12.8 cases per million person-years (Baker, 2022).
Maomao Ai, Tao Lin, Ruoyu Guo, Haiyao Zheng, Haiyan Deng, Feng Yu   +5 more
doaj   +1 more source

Light and heavy chain deposition disease with focal amyloid deposition diagnosed with mass spectrometry: a case report

BMC Nephrology, 2023
Background Light and heavy chain deposition disease (LHCDD) is a rare condition characterised by the deposition of immunoglobulin components in the kidneys.
Yuki Shimamoto, Naoki Takahashi, Nagaaki Katoh, Yuki Matsui, Yusuke Mochizuki, Masanori Ito, Masahide Yazaki, Fuyuki Kametani, Kenji Kasuno, Yoshiki Sekijima, Hironobu Naiki, Masayuki Iwano   +11 more
doaj   +1 more source

Human Autoantibody Silencing by Immunoglobulin Light Chains [PDF]

The Journal of Experimental Medicine, 2004
Several newly arising human antibodies are polyreactive, but in normal individuals the majority of these potentially autodestructive antibodies are removed from the repertoire by receptor editing or B cell deletion in the bone marrow. To determine what proportion of naturally arising autoantibodies can be silenced by immunoglobulin (Ig) light chain ...
Michel C. Nussenzweig, Michel C. Nussenzweig, Hedda Wardemann, Johanna Hammersen   +3 more
openaire   +3 more sources

Insights into PI3K/AKT signaling in B cell development and chronic lymphocytic leukemia

FEBS Letters, EarlyView.
This Review explores how the phosphoinositide 3‐kinase and protein kinase B pathway shapes B cell development and drives chronic lymphocytic leukemia, a common blood cancer. It examines how signaling levels affect disease progression, addresses treatment challenges, and introduces novel experimental strategies to improve therapies and patient outcomes.
Maike Buchner
wiley   +1 more source